Skip to main content
Equibles

MARSHALL WACE, LLP

Position in RARE — Ultragenyx Pharmaceutical Inc.

CIK 1318757 LONDON, X0
Back to RARE Full portfolio

Position in RARE

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$5,338,693
+$2,038,524 QoQ
Shares Held
159,889
+1.5% QoQ
Ownership
0.162%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#83
of 311 holders
Holding Since
Dec 2020
22 quarters on record
Voting authority Sole 0% Shared 100% None 0%

Common Shares in RARE Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

MARSHALL WACE, LLP holds $3,055,517,440 across 267 Biotechnology names. RARE ranks #102 (0.2% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 543,897 $270,169,956
2 INCY
Incyte Corp
 1,310,154 $148,519,056
3 RPRX
Royalty Pharma plc
 2,450,669 $137,409,009
4 SYRE
Spyre Therapeutics, Inc.
 991,693 $88,042,503
5 ALNY
Alnylam Pharmaceuticals, Inc.
 259,799 $78,207,292
6 TVTX
Travere Therapeutics, Inc.
 1,333,207 $75,739,488
7 MANE
Veradermics, Inc
 585,560 $71,988,746
8 DFTX
Definium Therapeutics, Inc.
 1,298,946 $61,102,419

All Filings in RARE

Export CSV
22 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $5,338,693 159,889
2026-03-31 $3,300,169 157,526
2025-12-31 $1,659,864 72,168
2025-09-30 $4,394,507 146,094
2025-06-30 $2,395,069 65,871
2025-03-31 $12,096,964 334,078
2024-12-31 $44,239,675 1,051,573
2024-09-30 $45,662,766 822,012
2024-06-30 $46,570,410 1,133,100
2024-03-31 $45,242,143 968,990
2023-12-31 $71,227,220 1,489,486
2023-09-30 $33,538,200 940,763
2023-06-30 $42,745,764 926,637
2023-03-31 $36,311,552 905,525
2022-12-31 $15,540,240 335,425
2022-09-30 $3,342,366 80,714
2022-06-30 $20,979,439 351,650
2022-03-31 $27,991,596 385,453
2021-12-31 $19,696,400 234,230
2021-09-30 $2,700,468 29,942
2021-06-30 $3,387,690 35,529
2020-12-31 $3,601,118 26,014